Introduction
Malignant clonal plasma cells (PCs) that characterize multiple myeloma (MM) derived from post-follicular B cells in which a primary oncogenic event occurred, usually during switch class recombination. 1 After homing in the bone marrow (BM), myeloma cells have proliferative and survival advantages over their normal counterpart, because they interact with the microenvironment leading to overexpression of adhesion molecules and to secretion of various chemokines and cytokines, the most important of which is interleukin-6 (IL-6). 2 Favored by genomic instability, myeloma cells subsequently acquired additional oncogenic events resulting in disease progression and drug resistance. 3 Interactions between malignant PC and BM stromal cells not only influence myeloma cell growth and survival, but also promote bone destruction and angiogenesis. 4, 5 BM microenvironment contains a complex reticulum of nonhematopoietic cells, mainly of mesenchymal origin, which provide support for growth, proliferation and differentiation of the hematopoietic stem cells and their progeny. Within these cells defining the hematopoietic niche, a population of multipotential progenitors, referred to as mesenchymal stem cells (MSCs), has been identified. MSCs are progenitor cells capable of giving rise and differentiate along the lines of the bone, cartilage, muscle and fat. 6 Although lacking specific markers, these cells can be identified by the expression of surface markers such as CD73, CD90, integrins and adhesion molecules 7, 8 in addition to the absence of expression of CD34 and CD45 hematopoietic-related antigen. Besides their differentiation capacities, MSCs have been shown to exhibit immune modulatory functions. They inhibit or suppress several T-cell functions [9] [10] [11] and also modulate B-cell proliferation, 12 dendritic cells maturation and proliferation 13 and closely interact with natural killer cells. 14 Although a role of the BM microenvironment in the pathogenesis of MM is clearly established, 15, 16 whether or not it depends on primary or secondary abnormalities of BM cells remains open to question. To solve this issue, we studied functions and differentiating capacities of MSCs derived from myeloma patients. We found that myeloma MSCs were able to sustain normal growth of hematopoietic stem cells and to differentiate in adipogenic and osteogenic lineages. Conversely, they expressed altered immunomodulatory functions and produced abnormally high levels of IL-6. These abnormalities were observed in the absence of any detectable myeloma cells, suggesting that MSCs from MM patients harbor intrinsic abnormalities that may play a key role in the emergence of the disease and/or in the occurrence of relapse.
Materials and methods

Patients
We studied 61 consecutive patients with myeloma (n ¼ 56), plasma cell leukemia (n ¼ 1) or monoclonal gammapathy of unknown significance (MGUS, n ¼ 4). The median age was 61 years (range, 28-81 years). Of the 56 myeloma patients, 40 were newly diagnosed, of which 28 had a stage I or II of the disease and 12 a stage III. All were studied before any chemotherapy treatment. Sixteen patients were in relapse of the disease and off therapy since at least 3 months at the time of the study. All patients gave informed consent. Cytogenetic abnormalities detected in purified PCs were a t(4;14) rearrangement in 10/61 patients, a deletion 17p13 in 1/23, and a deletion 13q14 in 10/ 23. As a control, 13 healthy donors BM samples were obtained from filters used during BM processing for allogeneic transplantation.
Cell culture
Patients and healthy donors BM cells obtained after Ficoll (Invitrogen, Cergy-Pontoise, France) were cultured at the initial density of 5 Â 10 4 cells/cm 2 in minimum essential medium-a (Invitrogen, Cergy-Pontoise, France), supplemented with 10% defined fetal calf serum (DFBS, HyClone, Logan, UT, USA), L-glutamine (2 mM; Invitrogen), basic fibroblast growth factor (bFGF) (1ng/ml; R&D Systems, Lille, France), antibiotic/antimycotic (Invitrogen). After 24-48 h, non-adherent cells were removed and medium was changed. Cultures were fed every 2 or 3 days until confluence. Adherent cells were then trypsinized, harvested and cultured by seeding 1 Â 10 3 cells/cm 2 .
Immunophenotyping of MSCs
MSCs were stained with antibodies directed to CD34, CD45, CD73, CD90, CD13, CD49e, CD44 or matched isotype control (all purchased from Becton Dickinson, Le Pont de Claix, France) and with anti-CD138 antibody to assess a potential contamination with residual plasma cells. Immunofluorescence analysis was performed by using a five-parameter flow cytometer (FACScalibur, Becton Dickinson, San Jose, CA, USA).
Adipogenic differentiation of MSCs
MSCs were incubated in six-well microplates in Dubelcco's modified Eagle's medium (DMEM) with 1 g/l glucose supplemented with 20% foetal bovine serum (FBS), 0.5 mM isobutylmethylxanthine (Sigma Aldrich, Saint Quentin Fallavier, France), 60 mM indomethacin (Sigma), 10 À6 M dexamethasone (Sigma) and 5 mg/ml insulin. The medium was replaced every 3-4 days for 21 days. The cells containing lipid vacuoles were observed within 2-3 weeks.
Osteogenic differentiation of MSCs
MSCs were incubated in six-well microplates in DMEM with 4.5 g/l glucose supplemented with 10% FBS, 10 À7 M dexamethasone, 50 mg/ml ascorbic acid and 3mM inorganic acid. The medium was replaced every 3-4 days for 21 days. Culture was washed with Dulbecco's phosphate-buffered saline (DPBS), fixed in a solution of cold 70% ethanol for 15 min and stained for alkaline phosphatase (ALP) activity or alizarin red. ALP activity was determined on fixed cells incubated for 10 min with 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium (BCIP/NBT) buffered substrate (Sigma). For alizarin red assay, fixed cells were stained for 10 min with 1 ml of 40 mM alizarin red (Sigma) in order to assess calcium accumulation. 
Mixed lymphocyte reactions
MSCs-mediated support of hematopoiesis
MSCs were irradiated (25 Gy) by using a cesium irradiator and subcultured at a concentration of 3 Â 10 4 MSCs per well in 96-well plates in myelocult medium (Stemcell Technologies, Grenoble, France) with 10 À6 M hydrocortisone. The plates were recharged with 100, 200 or 500 CD34 þ cells/well and incubated for 5 weeks with weekly culture refeeding. Fifteen replicate wells per dilution were established. Weekly, the entire content of three wells of each dilution was harvested: nonadherent and adherent cells were plated into 24-well with 0.5 ml/well of complete methylcellulose medium (Stem alpha, Saint Clement les Places, France) and maintained at 371C in 5% CO 2 . Colony-forming cells (CFC) quantification in each well was evaluated at day 14.
Measurement of IL-6 levels
Human IL-6 levels in culture supernatants were measured using the Becton Dickinson Cytometric Bead Array bead-based immunoassay, following the manufacturer's instructions. Briefly, IL-6 capture beads were incubated with calibrators (standards ranging from 0 to 5000 pg/ml) or samples and incubated 1 h in the dark. Anti-IL-6 phycoerythrin labelled antibody was then added and the mixture was subsequently incubated for 2 h in the dark. After washing, a two-color flow cytometry analysis was performed and data were acquired and analyzed using Becton Dickinson FCAP Array software. IL-6 concentrations in culture supernatants from patients and controls were determined from standard curves.
Cytogenetic analysis
PCs from BM were CD138-selected using MACS systems (Miltenyi Biotec, Bergisch-Gladbach, Germany). The t(4;14) IGH-MMSET rearrangement was searched for in PCs in the 61 patients using a real-time quantitative PCR (RQ-PCR) assay adapted from Chesi et al. 17 This assay efficiently detects the three IGH-MMSET fusion transcript families in large series of MM patients, using three RQ-PCR systems that are normalized to the housekeeping gene GUS expression (Crinquette et al., Blood 2003; 102: 5219, abstract). RQ-PCR-positive MM cases were confirmed by flourescence in situ hybridization (FISH) using the Vysis LSI IGH/FGFR3 Dual Color Probe (Vysis-Abbott, Voisins-le-Bretonneux, France). In addition, chromosomal deletions 13q14 and 17p13 were searched in PCs of 23/61 patients using the D13S319 (Amplitech, Compiègne, France) and the LSI p53 SpectrumOrange (Vysis-Abbott) FISH probes hybridized on interphasic purified cells. Five patients with IGH-MMSET expression in PCs and available frozen MSCs materials were analysed for IGH-MMSET expression. As in PCs, MSCs RNAs were extracted using the Rneasy kit (Qiagen, Courtaboeuf, France) and the IGH-MMSET transcripts were searched for. MSCs cells were also analysed by interphasic FISH in three additional patients with a 13q14 deletion in PCs, and one patient with a 17p13 deletion.
Statistical analysis
Student's t-test for paired data was used to test the probability of significant differences between samples. A value of Po0.05 was used to define statistical significance.
Results
Amplification potential of BM MSCs
Confluent MSCs cultures were obtained for 52 out of 61 patients and for all controls after 19.5 and 19 days, respectively. MSCs were not obtained in nine patients, independently of the stage of the disease (four stage I, one stage II, three relapse, one MGUS). There were no statistically significant differences between the number of generated MSC per cm 2 and the patients age (P ¼ 0.69) or the disease status (relapsing vs newly diagnosed MM, P ¼ 0.62).
Flow-cytometric data
Fluorescence-activated cell sorting (FACS) analysis of MSCs from patients and healthy controls are presented in Table 1 . In all cases, MSCs phenotypes were analyzed at passage 2. Patients and control MSCs displayed similar antigen expression (P40.05 for each antigen tested) with no expression of hematopoietic lineage antigens such as CD34 and CD45 and high expression of CD73, CD90, CD13, integrin (CD49e) and adhesion molecules (CD44). In an attempt to confirm that patient MSCs were devoid of any contamination by plasma cells, cultured cells were stained with anti-CD138 antibody. FACS analysis did not significantly detect CD138-positive cells in any case except in one, where CD138-positive cell percentage was 4.5%, thus demonstrating that contamination of MSCs culture by MM cells was unlikely.
In vitro differentiation of MM MSCs
MSCs were cultured under standard conditions for adipogenic and osteogenic differentiation in 15 patients and five controls. In the adipogenic induction medium, both patient MSCs and control MSCs showed accumulation of lipid-rich vacuoles within the cells (Figure 1a and b) . Lipid droplets appeared in MSCs cytoplasm after 2 weeks, the amount and volume of droplets increasing in a time-dependent manner. When cultured in monolayer osteogenic conditions, patient and control MSCs acquire an osteoblastic morphology demonstrated by an upregulation of ALP activity and deposition of a calcium-rich mineralized extracellular matrix (Figure 1c-f) . These findings suggest that adipogenesis and osteogenesis of MSCs from MM patients are qualitatively conserved, even if it cannot be prejudged whether or not quantitative differences should exist between patients and healthy donors.
Effect of MM MSCs on MLR
The effect of patient MSCs (n ¼ 12) on PBMC proliferation was evaluated by mixing MSCs and allogeneic PBMCs at four different ratios. Of these 12 patients, six had stage I MM, four a stage III and two were in relapse of the disease. As expected, 9, 18 MSCs from normal donors (n ¼ 4) inhibited MLR in a dosedependent manner with, at ratio of 1/5, 1/10, 1/100 and 1/1000, mean percentages of inhibition of 91, 74, 51 and 20%, respectively ( Figure 2 ). Patient MSCs also exhibited a dosedependent inhibitory effect but with significantly less efficiency than control MSCs. Indeed, for the former, at ratio of 1/5 and 1/10, mean percentages of inhibition were 40 and 19%, respectively (Po0.05 and o0.01). At ratios of 1/100 and 1/1000, patients MSCs were no more inhibitory (mean percentage of inhibition of À16 and À12%, respectively). These findings show an altered capacity of MM MSCs to inhibit or suppress T-cell proliferation, even if a partial inhibition was obtained at high MSC concentration.
Long-term hematopoiesis support
Irradiated MSC layers obtained from myeloma patients (n ¼ 8) and normal controls (n ¼ 6) were recharged with different CD34 þ cell concentration (100, 200 or 500). As shown in Figure 3 , the number of CFCs obtained weekly over a period of 5 weeks did not differ significantly between patients and control subjects, whatever the CD34 þ cells concentration tested (P40.05 between patients and controls for each conditions). As expected, a dose-dependent relationship was observed in both groups between the number of inoculated CD34 þ cells and the number of CFCs at the end of culture. These results strongly suggest the ability of MM MSCs to support the growth of normal hematopoietic stem cells.
IL-6 in MSCs supernatants
The levels of IL-6 in the culture supernatants of confluent MSCs were determined in both myeloma (n ¼ 29) and MGUS (n ¼ 3) patients and compared to control MSCs (n ¼ 11). All experiments were performed on supernatants harvested just before the second MSCs passage. MM patients displayed significantly higher IL-6 concentrations (16 53072871 pg/ml, median 11 751 pg/ml, range 125-74 819 pg/ml, Figure 4 ) compared with the normal donors (668571213 pg/ml, median 4998 pg/ml, range 2710-14 005 pg/ml; P ¼ 0.01). No significant differences were found between MGUS patients and normal controls, but 
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only three MGUS could be tested for IL-6 production. The relationship between the percentage of PCs in patients BM at diagnosis and IL-6 production by MSCs of the same patients was also analyzed. We did not find any correlation between these parameters (r 2 ¼ 0.010, P ¼ 0.74). Taken together, these data suggest that myeloma MSCs produces high levels of IL-6, independently of PCs-mediated stimulation. Moreover, in our hands, IL-6 production was not associated with the stage of the disease or with the presence of cytogenetic abnormalities.
Cytogenetic analysis in MM MSCs
We investigated MSCs in eight MM patients who showed cytogenetic clonal markers in the PCs. In contrast with PCs, no t(4;14), del(13q14) and del(17p13) were evidenced in the MSCs in five, three and one patients, respectively, using RQ-PCR and FISH ( Figure 5 ). Thus, MSCs obtained from patients with MM do not exhibit chromosomal abnormalities detectable in their myeloma cells counterparts.
Discussion
This study aimed to evaluate the intrinsic characteristics of MSCs from MM patients. These cells expressed the 'typical' expected phenotype 8 and had hematopoiesis-supporting capacities similar to those of normal MSCs. Adipogenic and osteogenic differentiating capacities of MSCs of both origin were also similar, at least from a qualitative point of view. In contrast, MSCs derived from myeloma patients produced in average 2.5-fold more IL-6 than MSCs from normal donors and were less immunosuppressive than their normal counterparts. All these abnormalities appeared independent of patient's age and tumor burden (P ¼ 0.69 and 0.7, respectively) and were equally distributed, whatever the disease status.
Only few studies on patient MSCs were reported. In one study of MSCs obtained from patients with various hematological malignancies (including 11 MM), minor and transient atypical surface expression of some antigens were observed, proliferative capacity appeared normal and no functional properties were assessed. 19 In contrast, many studies demonstrated an abnormal production of IL-6 that was thought to be dependent on close contact with tumor cells, 20 supporting a paracrine role of this cytokine in tumor cell growth and survival. [21] [22] [23] The source of IL-6 was considered to be stromal 'elements' without further characterization. Our data demonstrate that MSCs indeed take part in the overproduction of IL-6.
In our study, IL-6 overproduction by MSCs was detected up to 3 weeks of culture in conditions that rendered unlikely the persisting presence of myeloma cells. This was confirmed by FACS analyses that were performed at different steps of the culture and detected virtually no contaminating CD138-positive cells. Moreover, in those cases featured by well-defined traceable molecular aberrations in malignant cells, PCR studies gave negative results ruling out a contamination not only by mature PCs, but also by less differentiated precursors of the malignant clone. These data were in accordance with the absence of correlation between the amount of IL-6 production by MSCs, the degree of the PC infiltration at the moment of the BM harvest and the disease's stage. Interestingly, high levels of IL-6 were observed not only in patients with stage II-III disease but also in patients with stage I disease. Concerning MGUS, we observed no IL-6 overproduction in any of the three studied cases but additional patients should be studied before drawing any conclusion.
As it does not require the presence of myeloma cells, the overproduction of IL-6 appears to be an intrinsic property of MSCs from MM patients. Such property might precede the myeloma seeding and might be a pre-requisite for survival, proliferation and differentiation of the myeloma cell. This is illustrated by the plasmocytomas that can be obtained in some mice model in which the PC proliferation develop in close contact with IL-6-producing inflammatory feeder cells that are induced by peritoneal irritation. 24 Hyperproduction of the parathyroid hormone, which results in high IL-6 production in the BM, might also favor the emergence of a PC proliferation. 25 Alternatively, instead of being involved in the early step of the MM emergence, IL-6 overproduction by MSCs might result from transforming effect of the myeloma cells that would persist in remission favoring the occurrence of a subsequent relapse. In order to solve these issues, longitudinal studies of patients at different steps of their disease course are ongoing.
Recent data showed that microvascular endothelial cells (ECs) in B-cell lymphomas are in part tumor-related 26 and that circulating ECs of myeloma patients with 13q14 deletion can carry the same chromosomal aberration as the neoplastic PC. 27 In contrast to ECs and PCs that could derive from a common hemangioblast precursor, an origin of MSCs and malignant PCs from a common mesenchymal and hematopoietic precursor appears unlikely. This was confirmed by the study of myeloma patients with traceable molecular aberrations, particularly the t(4,14) translocation, in whom FISH and PCR experiments did not detect the molecular marker in the MSCs. These negative results did not document neither the putative plasticity of myeloma cells, mimicking the activity of stromal cells nor the intercellular transmission of chromosomal material that were suggested in other tumor models. 28 Finally, oncogenic events or cytogenetic abnormalities other than those associated with MM, leading to a constitutive IL-6 production by MM MSCs, cannot be ruled out.
Suppression of allogeneic T-cell proliferation is a known property of normal MSCs. Such suppressive effect is thought to be mediated by cell-cell contact, immunosuppressive cytokine production as transforming growth factor (TGF)-b or IL-10, or nitric oxide synthase (NOS) activation (Sato et al., Blood 2005; 106: 1393, abstract). 11, 29 We found that the ability of MSCs from MM patients to suppress allogeneic T-cell proliferation was altered as compared to that of MSCs derived from normal bone marrow. The role of the altered capacity to inhibit T-cell proliferation in the transformation of plasma cells or in MM progression remains to be clarified. One could hypothesize that a reduced production of TGF-b by MM MSCs could lead both to a less immunosuppressive effect and to a reduced apoptosis of malignant plasma cells.
In summary, MSCs that can be derived from BM of myeloma patients exhibit normal differentiation and hematopoietic support capacities but overproduce IL-6 and have a reduced immunosuppressive efficiency as compared to normal MSCs. These properties persist in the absence of myeloma cells and are not associated with the chromosome aberration that features the tumor cells. They likely create an environment prone to the emergence of the malignant clone and/or to the occurrence of relapse. Whether or not these abnormalities can be primary or are acquired at the contact of the myeloma clone itself remains to be determined.
